1,2,3,4-四氢-6-异喹啉溴酸盐 | 59839-23-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 1,2,3,4-四氢-6-异喹啉溴酸盐
• 中文别名: 1,2,3,4-四氢异喹啉-6-醇氢溴酸盐
• 英文名称: 6-hydroxy-1,2,3,4-tetrahydroisoquinoline hydrobromide
• 英文别名: 1,2,3,4-tetrahydroisoquinolin-6-ol hydrobromide；1,2,3,4-tetrahydro-6-hydroxy-isoquinoline-hydrobromide；1,2,3,4-tetrahydroisoquinolin-6-ol;hydrobromide
• CAS: 59839-23-5
• 化学式: BrH*C₉H₁₁NO
• 分子量: 230.104
• InChiKey: USVPGYXADKFDAI-UHFFFAOYSA-N

物化性质

• 熔点：
  196.7-197.8℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.62
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  32.3
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 海关编码：
  2933499090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢-6-异喹啉溴酸盐 在 盐酸 、 四(三苯基膦)钯 、 三乙胺 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 82.32h， 生成 2-(2-Methyloxirane-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-6-carbonitrile
  参考文献：
  名称：

  1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)indoline-4-carbonitrile Derivatives as Potent and Tissue Selective Androgen Receptor Modulators

  摘要：

  We present a novel series of selective androgen receptor modulators (SARMs) which shows excellent biological activity and physical properties. 1-(2-Hydroxy-2-methyl-3-phenoxypropanoyl)-indoline-4-carbonitriles showed potent binding to the androgen receptor (AR) and activated AR-mediated transcription in vitro. Representative compounds demonstrated diminished activity in promoting the intramolecular interaction between the AR carboxyl (C) and amino (N) termini. This N/C-termini interaction is a biomarker assay for the undesired androgenic responses in vivo. In orchidectomized rats, daily administration of a lead compound from this series showed anabolic activity by increasing levator ani muscle weight. Importantly, minimal androgenic effects (increased tissue weights) were observed in the prostate and seminal vesicles, along with minimal repression of circulating luteinizing hormone (LH) levels and no change in the lipid and triglyceride levels. This lead compound completed a two week rat toxicology study, and was well tolerated at doses up to 100 mg/kg/day, the highest dose tested, for 14 consecutive days.

  DOI：

  10.1021/jm401625b
• 作为产物：
  描述：

  3-甲氧基苯乙基氨基甲酸乙酯 在 lithium aluminium tetrahydride 、 氢溴酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.08h， 生成 1,2,3,4-四氢-6-异喹啉溴酸盐
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRIDINE DERIVATIVES AS FABI INHIBITORS
  [FR] DÉRIVÉS DE PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE FABI

  摘要：

  本发明提供了式(I)的取代吡啶衍生物，其可能作为抗细菌剂，特别是FabI抑制剂，具有治疗用途。式(I)中，R1至R5和L具有说明书中给出的含义，以及用于治疗和预防疾病或失调的药用可接受盐，特别是在有优势使用抗细菌剂，尤其是FabI抑制剂的疾病或失调中的用途。本发明还提供了合成和管理FabI抑制剂化合物的方法。本发明还提供了包含至少一种FabI抑制剂化合物和用于其的药用可接受载体、稀释剂或助剂的药物制剂。

  公开号：

  WO2013080222A1

文献信息

• Synthesis of 2-substituted tetrahydroisoquinolin-6-ols: potential scaffolds for estrogen receptor modulation and/or microtubule degradation
  作者：Tanya Mabank、Kabamba B. Alexandre、Stephen C. Pelly、Ivan R. Green、Willem A. L. van Otterlo

  DOI：10.24820/ark.5550190.p010.962

  日期：——

  Copyright: 2019 ARKAT USA INC. Content is disseminated under a Creative Commons Attribution License (CC BY)

  版权所有：2019 ARKAT USA INC. 内容根据知识共享署名许可 (CC BY) 传播
• [EN] SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS<br/>[FR] COMPOSÉS DE TÉTRAHYDROISOQUINOLINE SUBSTITUÉS UTILES COMME AGONISTES DU GPR120
  申请人：MERCK SHARP & DOHME

  公开号：WO2017205193A1

  公开（公告）日：2017-11-30

  The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.

  本发明涉及一种由公式(I)表示的化合物，以及披露了治疗或预防糖尿病、高脂血症、肥胖、非酒精性脂肪肝炎（NASH）、炎症相关疾病及相关疾病和状况有用的药用可接受盐。这些化合物作为G蛋白偶联受体GPR120的激动剂是有用的。还包含了药物组合物和治疗方法。
• Bronchorelaxing compounds
  申请人：Skogvall Staffan

  公开号：US20050165004A1

  公开（公告）日：2005-07-28

  A compound of the general formula (I) including its pharmaceutically acceptable acid addition salts wherein A is CHR 9 , wherein R 9 is H, C 1 -C 6 alkyl; n is 1-3; B is CHR 10 , wherein R 10 is H, C 1 -C 6 alkyl; m is 1 or 2; D is O or S or optionally NR 16 , wherein R 16 is H, C 1 -C 6 alkyl or C 2 -C 6 acyl; E is CR 11 R 12 or NR 13 , wherein R 11 and R 12 are, independent of each other, H or C 1 -C 6 alkyl, R 13 is H or C 1 -C 6 alkyl; F is C 1 -C 18 alkyl which may be mono- or di-unsaturated and/or substituted, is useful in treating and preventing pulmonary disease characterized by bronchoconstriction. Also disclosed are pharmaceutical compositions comprising the compound and methods for their manufacture.

  通用式（I）的化合物及其药学上可接受的酸盐包括其中 其中A为CHR 9 ，其中R 9 为H，C 1 -C 6 烷基；n为1-3；B为CHR 10 ，其中R 10 为H，C 1 -C 6 烷基；m为1或2；D为O或S或可选地为NR 16 ，其中R 16 为H，C 1 -C 6 烷基或C 2 -C 6 酰基；E为CR 11 R 12 或NR 13 ，其中R 11 和R 12 独立地为H或C 1 -C 6 烷基，R 13 为H或C 1 -C 6 烷基；F为C 1 -C 18 烷基，可以是单烯或双烯和/或取代的，用于治疗和预防以支气管痉挛为特征的肺部疾病。还公开了包含该化合物的药物组合物及其制备方法。
• NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS
  申请人：Diaz Caroline Jean

  公开号：US20100222345A1

  公开（公告）日：2010-09-02

  This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

  这项发明涉及新型化合物，它们是阿片受体的拮抗剂或逆向激动剂之一，以及含有它们的药物组合物，它们的制备过程，以及它们在治疗中的应用。
• Amidine compounds
  申请人：Japan Tobacco Inc.

  公开号：US06562828B1

  公开（公告）日：2003-05-13

  A compound of the formula [I] wherein R1, R2 and R3 are the same or different and each is hydrogen atom, wherein each symbol is as defined in the specification, a salt thereof or a prodrug thereof. The compound of the present invention, a salt thereof and a prodrug thereof are useful as factor Xa inhibitor and blood coagulation inhibitor, and are useful for the prophylaxis and/or treatment of diseases caused by blood coagulation or thrombus.

  其中R1、R2和R3相同或不同，且每个都是氢原子，其中每个符号如规范中定义，其盐或前药。本发明的化合物及其盐和前药可用作因子Xa抑制剂和抗凝血剂，对于预防和/或治疗由血液凝固或血栓引起的疾病有用。